These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 12877674)

  • 1. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma.
    Shimoni A; Hardan I; Avigdor A; Yeshurun M; Raanani P; Ben-Bassat I; Nagler A
    Br J Haematol; 2003 Aug; 122(3):457-64. PubMed ID: 12877674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
    Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS
    Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma.
    Shortt J; Spencer A
    Bone Marrow Transplant; 2006 Sep; 38(6):433-6. PubMed ID: 16892074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.
    Villa D; George A; Seymour JF; Toze CL; Crump M; Lee C; Buckstein R; Stewart DA; MacDonald D; Foley R; Xenocostas A; Sabloff M; Chua N; Couture F; Larouche JF; Cohen S; Savage KJ; Connors JM; Panzarella T; Carney DA; Dickinson M; Kuruvilla J
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1813-8. PubMed ID: 25042735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).
    Joyce RM; Regan M; Ottaway J; Umiel T; Tetreault JC; Levine J; McDermott D; Hurley D; Giallombardo N; Smith T; Lamontagne D; Uhl L; Avigan D
    Ann Oncol; 2003; 14 Suppl 1():i21-7. PubMed ID: 12736227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
    Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
    Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
    Horwitz SM; Negrin RS; Blume KG; Breslin S; Stuart MJ; Stockerl-Goldstein KE; Johnston LJ; Wong RM; Shizuru JA; Horning SJ
    Blood; 2004 Feb; 103(3):777-83. PubMed ID: 12907446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
    Khouri IF; Saliba RM; Hosing C; Okoroji GJ; Acholonu S; Anderlini P; Couriel D; De Lima M; Donato ML; Fayad L; Giralt S; Jones R; Korbling M; Maadani F; Manning JT; Pro B; Shpall E; Younes A; McLaughlin P; Champlin RE
    J Clin Oncol; 2005 Apr; 23(10):2240-7. PubMed ID: 15800314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation.
    Ratanatharathorn V; Logan B; Wang D; Horowitz M; Uberti JP; Ringden O; Gale RP; Khoury H; Arora M; Spellman S; Cutler C; Antin J; Bornhaüser M; Hale G; Verdonck L; Cairo M; Gupta V; Pavletic S;
    Br J Haematol; 2009 Jun; 145(6):816-24. PubMed ID: 19344418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma.
    Clavert A; Le Gouill S; Brissot E; Dubruille V; Mahe B; Gastinne T; Blin N; Chevallier P; Guillaume T; Delaunay J; Ayari S; Saulquin B; Moreau A; Moreau P; Harousseau JL; Milpied N; Mohty M
    Leuk Lymphoma; 2010 Aug; 51(8):1502-8. PubMed ID: 20583964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.
    Belhadj K; Delfau-Larue MH; Elgnaoui T; Beaujean F; Beaumont JL; Pautas C; Gaillard I; Kirova Y; Allain A; Gaulard P; Farcet JP; Reyes F; Haioun C
    Ann Oncol; 2004 Mar; 15(3):504-10. PubMed ID: 14998857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
    Shimoni A; Zwas ST; Oksman Y; Hardan I; Shem-Tov N; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A
    Exp Hematol; 2007 Apr; 35(4):534-40. PubMed ID: 17379063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders.
    Cerny J; Trneny M; Slavickova A; Pytlik R; Salkova J; Valkova V; Liu Q; Houghton J; Klener P
    Hematology; 2009 Aug; 14(4):187-97. PubMed ID: 19635181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma.
    Tsirigotis P; Dray L; Resnick IB; Ackerstein A; Gesundheit B; Elad S; Or R; Shapira MY
    Ann Hematol; 2010 Mar; 89(3):263-72. PubMed ID: 19693502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience.
    Nachbaur D; Oberaigner W; Fritsch E; Nussbaumer W; Gastl G
    Eur J Haematol; 2001 Jan; 66(1):43-9. PubMed ID: 11168507
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.